Potent Immune Activation in Chronic Hepatitis C Patients upon Administration of An Oral Inducer of Endogenous Interferons that Acts via Toll-Like Receptor 7

Abstract

Background

ANA773, an oral prodrug of a small-molecule Toll-like receptor (TLR)7 agonist, induces a dose-related decrease in serum HCV RNA levels in chronic hepatitis C patients.

Methods

The prodrug ANA773 was administered to healthy individuals and chronic hepatitis C patients. At different time points during the course of treatment, modulation of the phenotype and function of peripheral leukocytes were evaluated to determine the role of distinct immune cells on the clinical outcome of therapy.

Results

Early after administration of the TLR7 agonist, a mild transient reduction of the number of lymphocytes was observed in both healthy individuals and chronic hepatitis C patients. Moreover, repeated administration of ANA773 resulted in transiently reduced numbers of myeloid and plasmacytoid dendritic cells (DC) in blood.

Interestingly, reduced plasmacytoid DC numbers as well as increased serum interferon (IFN)-α and IFN-γ inducible protein (IP)-10 levels were observed only in virological responders (≥1 log₁₀ IU/ml reduction of HCV RNA levels upon ANA773 treatment), but were absent in virological non-responders. In vitro stimulation of peripheral blood mononuclear cells from virological responders showed a high frequency of IFN-α-producing plasmacytoid DC upon stimulation in vitro with ANA773, whereas no IFN-α was induced in non-responders.

Conclusions

These findings indicate that the viral load decline in chronic hepatitis C patients treated with the TLR7 agonist ANA773 is likely due to intrinsic differences in the induction of endogenous IFNs and IFN-stimulated gene products (IFN-α and IP-10) upon TLR7 ligation.

References

Shepard

C.W.

, Finelli

, Alter

M.J.

Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558–567.

Seeff

L.B.

Natural history of chronic hepatitis C. Hepatology 2002; 36 Suppl 1: S35–S46.

Shoukry

N.H.

, Cawthon

A.G.

, Walker

C.M.

Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu Rev Microbiol 2004; 58: 391–424.

Rehermann

, Nascimbeni

Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215–229.

Dustin

L.B.

, Rice

C.M.

Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol 2007; 25: 71–99.

Boonstra

, Woltman

A.M.

, Janssen

H.L.

Immunology of hepatitis B and hepatitis C virus infections. Best Pract Res Clin Gastroenterol 2008; 22: 1049–1061.

Houghton

, Abrignani

Prospects for a vaccine against the hepatitis C virus. Nature 2005; 436: 961–966.

Akira

, Takeda

Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499–511.

Iwasaki

, Medzhitov

Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987–995.

10.

Kadowaki

, Ho

, Antonenko

Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194: 863–870.

11.

Shortman

, Liu

Y.J.

Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002; 2: 151–161.

12.

Ito

, Amakawa

, Kaisho

Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 2002; 195: 1507–1512.

13.

Horsmans

, Berg

, Desager

J.P.

Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005; 42: 724–731.

14.

Pockros

P.J.

, Guyader

, Patton

Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind Phase IIa studies. J Hepatol 2007; 47: 174–182.

15.

Liu

B-S

, Groothuismink

Z.M.A.

, Janssen

H.L.A.

, Boonstra

Role for IL-10 in inducing functional impairment of monocytes upon TLR4 ligation in patients with chronic HCV infections. J Leukoc Biol 2011; 89: 981–988.

16.

Bergmann

J.F.

, de Bruijne

, Hotho

Anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. Aliment Pharmacol Ther 2011; 34: 443–453.

17.

Thomas

, Laxton

, Rodman

, Myangar

, Horscroft

, Parkinson

Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection. Antimicrob Agents Chemother 2007; 51: 2969–2978.

18.

Yonkers

N.L.

, Rodriguez

, Milkovich

K.A.

TLR ligand-dependent activation of naive CD4 T cells by plasmacytoid dendritic cells is impaired in hepatitis C virus infection. J Immunol 2007; 178: 4436–4444.

19.

Simone

, Tortorella

, Zaccaro

, Napoli

, Antonaci

Impairment of TLR7-dependent signaling in dendritic cells from chronic hepatitis C virus (HCV)-infected non-responders to interferon/ribavirin therapy. J Clin Immunol 2010; 30: 556–565.

20.

Chang

, Kodys

, Szabo

Impaired expression and function of toll-like receptor 7 in hepatitis C virus infection in human hepatoma cells. Hepatology 2010; 51: 35–42.

21.

Kamphuis

, Junt

, Waibler

, Forster

, Kalinke

Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 2006; 108: 3253–3261.

22.

Schott

, Witt

, Neumann

Association of TLR7 single nucleotide polymorphisms with chronic HCV-infection and response to interferon-α-based therapy. J Viral Hepat 2008; 15: 71–78.

23.

Berghöfer

, Frommer

, Haley

, Fink

, Bein

, Hackstein

TLR7 ligands induce higher IFN-alpha production in females. J Immunol 2006; 177: 2088–2096.

24.

Castro

A.G.

, Neighbors

, Hurst

S.D.

Anti-interleukin 10 receptor monoclonal antibody is an adjuvant for T helper cell type 1 responses to soluble antigen only in the presence of lipopolysaccharide. J Exp Med 2000; 192: 1529–1534.

25.

Boonstra

, Rajsbaum

, Holman

Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals. J Immunol 2006; 177: 7551–7558.

26.

, Wagner

W.M.

, Gad

Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J Immunol 2010; 184: 5360–5367.